Delving into the Latest Updates on Caroverine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Caroverine (INN), Spasmium, Tinnex

Target

AMPA receptor x NMDA receptor

Mechanism

AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

PainSpasm

Inactive Indication

Labyrinth DiseasesTinnitus

Originator Organization-

Active Organization-

Inactive Organization

Phafag AG

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC22H27N3O2

InChIKeyMSPRUJDUTKRMLM-UHFFFAOYSA-N

CAS Registry23465-76-1

This trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom.
The study will investigate the transtympanic treatment with a 1,5 % caroverine solution.
Each patient will undergo treatment for 2 cycles of 48 hours each.

Start Date01 Jan 2011

Sponsor / Collaborator

Phafag AG

100 Clinical Results associated with Caroverine

Login to view more data

100 Translational Medicine associated with Caroverine

Login to view more data

100 Patents (Medical) associated with Caroverine

Login to view more data

40

Literatures (Medical) associated with Caroverine

01 Oct 2024·Indian Journal of Otolaryngology and Head & Neck Surgery

A Comparative Analysis of the Efficacy of Ginkgo Biloba and Caroverine in the Management of Idiopathic Tinnitus

Article

Author: Saxena, Rohit ; Basista, Hitender ; Pathak, Vivek Kumar ; Awasthi, Sanjeev

AimThe sound sensation that is experienced in the ears or brain and is unrelated to any external sources of stimulus is known as tinnitus. Tinnitus Functional Index (TFI) is used to establish the presence of the condition and determine symptom severity, its impact on the patient's quality of life, thus in this study, we aim to compare the efficacy of caroverine and Ginkgo Biloba in the management of idiopathic tinnitus using TFI.MethodsThis clinical study was conducted in at a tertiary care hospital in North India, for a duration of one year, among patients with chronic tinnitus. The sample size for this study consisted of 60 patients in each of three groups (caroverine, gingko biloba, and multivitamin). Assessments of TFI and pure-tone audiometry were performed to evaluate the efficacy of the two medications. The information pertaining to the subjects was kept anonymous and confidential. During data analysis, an association was significant for p value < 0.05.ResultsThe patients in three groups were matched for the age, gender and duration of tinnitus. At 6 months of medication with Ginkgo Biloba, patients experienced a significant (p < 0.0001) decrease of 50.0% in tinnitus of moderate severity, and a complete resolution of severe tinnitus symptoms with a percentage change of -100.0%.ConclusionIn our study, Ginkgo Biloba Group has significantly improved the severity of idiopathic tinnitus. Tinnitus has diverse underlying mechanisms, can be a symptom of various underlying diseases, and is challenging to measure. Further research is warranted to validate and explore these treatment options further.

01 Mar 2022·Allergy and Asthma ProceedingsQ3 · MEDICINE

Treatment strategies for postviral olfactory dysfunction: A systematic review

Q3 · MEDICINE

Review

Author: Vuncannon, Jackson R. ; Cozart, Ashley C. ; Adler, Jonah ; Jafari, Aria ; Kuruvilla, Merin E. ; Levy, Joshua M. ; Wise, Sarah K. ; Helman, Samuel N. ; Bennett, Sasha

Background: The coronavirus disease 2019 (COVID-19) pandemic has been associated with a dramatic increase in postviral olfactory dysfunction (PVOD) among patients who are infected. A contemporary evidence-based review of current treatment options for PVOD is both timely and relevant to improve patient care. Objective: This review seeks to impact patient care by qualitatively reviewing available evidence in support of medical and procedural treatment options for PVOD. Systematic evaluation of data quality and of the level of evidence was completed to generate current treatment recommendations. Methods: A systematic review was conducted to identify primary studies that evaluated treatment outcomes for PVOD. A number of medical literature data bases were queried from January 1998 to May 2020, with completion of subsequent reference searches of retrieved articles to identify all relevant studies. Validated tools for the assessment of bias among both interventional and observational studies were used to complete quality assessment. The summary level of evidence and associated outcomes were used to generate treatment recommendations. Results: Twenty-two publications were identified for qualitative review. Outcomes of alpha-lipoic acid, intranasal and systemic corticosteroids, minocycline, zinc sulfate, vitamin A, sodium citrate, caroverine, intranasal insulin, theophylline, and Gingko biloba are reported. In addition, outcomes of traditional Chinese acupuncture and olfactory training are reviewed. Conclusion: Several medical and procedural treatments may expedite the return of olfactory function after PVOD. Current evidence supports olfactory training as a first-line intervention. Additional study is required to define specific treatment recommendations and expected outcomes for PVOD in the setting of COVID-19.

01 Nov 2019·Indian Journal of Otolaryngology and Head & Neck Surgery

Randomised Controlled Clinical Study of Injection Caroverine and Ginkgo Biloba Extract in Cochlear Synaptic Tinnitus

Article

Author: Nishad, Rajeev Kumar ; Singh, Mangal ; Jain, Sanyogita ; Jain, Anil Kumar ; Verma, Reetu

Tinnitus, also known as phantom auditory perception, is an annoying symptom and 13-17% of population reports bothersome tinnitus. Cochlear synaptic tinnitus is the most common type. Many treatments have been tried but none is yet considered to be well established. To evaluate effect of Inj.Caroverine and Ginkgo Biloba extract in cochlear synaptic tinnitus in terms of improving tinnitus grading, tinnitus matching and quality of life of patient. It is Randomised controlled study, conducted in department of ENT, on 86 patients, who met inclusion criteria, divided into 4 groups. Gr1-Inj Caroverin, Gr2-Inj Placebo, Gr3-Ginkgo Biloba extract, Gr4-Placebo as extract. A single dose infusion of caroverine immediately improves tinnitus grading and matching and provides immediate relief in reducing severity of tinnitus in 54.54% cases but improvement was not sustained in caroverine group at 3 month and 6 month follow-up after infusion. Ginkgo biloba also is effective in improving tinnitus grading and matching in 31.8% cases and improvement was sustained in ginkgo biloba group even after 3 month of cessation of treatment i.e. at 6 month follow-up. It is suggested that Inj.Caroverine as intravenous infusion should be given in severe cases of tinnitus to reduce its severity immediately and then patient should be put on Tab.Ginkgo biloba for a period of 3 months to provide sustained and long lasting relief. Thus combination therapy of Inj.Caroverin and Tab.Ginkgo Biloba, appropriately tailored to the need of patient will provide better results in greater majority of patients.

100 Deals associated with Caroverine

Login to view more data